Literature DB >> 16314853

Regional heterogeneity in the haemodynamic responses to urotensin II infusion in relation to UT receptor localisation.

Sheila M Gardiner1, Julie E March, Philip A Kemp, Janet J Maguire, Rhoda E Kuc, Anthony P Davenport, Terence Bennett.   

Abstract

The aim of the study was to measure regional haemodynamic responses to 6 h infusions of human urotensin II (hUII), to identify possible mediators of the effects observed, and to relate the findings to the distribution of urotensin II receptors (UT receptors). Male, Sprague-Dawley rats had pulsed Doppler flow probes and intravascular catheters implanted for measurement of regional haemodynamics in the conscious, freely moving state. Infusions of saline (0.4 ml h(-1)) or hUII (30, 300 and 3,000 pmol kg(-1) h(-1)) were given i.v. for 6 h, and the effects of pretreatment with indomethacin (5 mg kg(-1) h(-1)), N(G)-nitro-L-arginine methyl ester (L-NAME, 3 mg kg(-1) h(-1)) or propranolol (1 mg kg(-1); 0.5 mg kg(-1) h(-1)) on responses to hUII (300 pmol kg(-1) h(-1) for 6 h) were assessed. Cellular localisation of UT receptor-like immunoreactivity was determined in relevant tissues. hUII caused dose-dependent tachycardia and hindquarters vasodilatation, accompanied by a slowly developing rise in blood pressure. Haemodynamic effects of hUII were attenuated by propranolol or L-NAME and abolished by indomethacin. UT receptor-like immunoreactivity was detected in skeletal and vascular smooth muscle. The findings indicate that in conscious rats, infusions of hUII cause vasodilatation, which, of the vascular beds monitored, is selective for the hindquarters and dependent on cyclooxygenase products and nitric oxide. The pressor effect of hUII under these conditions is likely to be due to an increase in cardiac output, possibly due to a positive inotropic effect. UT receptor-like immunoreactivity present in skeletal muscle is consistent with the haemodynamic pattern.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16314853      PMCID: PMC1751348          DOI: 10.1038/sj.bjp.0706503

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  26 in total

Review 1.  Vasodilatory mechanisms in contracting skeletal muscle.

Authors:  Philip S Clifford; Ylva Hellsten
Journal:  J Appl Physiol (1985)       Date:  2004-07

Review 2.  Human urotensin-II as a novel cardiovascular target: 'heart' of the matter or simply a fishy 'tail'?

Authors:  Stephen A Douglas
Journal:  Curr Opin Pharmacol       Date:  2003-04       Impact factor: 5.547

3.  Effect of human urotensin-II infusion on hemodynamics and cardiac function.

Authors:  Ghada S Hassan; Fazila Chouiali; Takayuki Saito; Fu Hu; Stephen A Douglas; Zhaohui Ao; Robert N Willette; Eliot H Ohlstein; Adel Giaid
Journal:  Can J Physiol Pharmacol       Date:  2003-02       Impact factor: 2.273

4.  Bolus injection of human UII in conscious rats evokes a biphasic haemodynamic response.

Authors:  Sheila M Gardiner; Julie E March; Philip A Kemp; Terence Bennett
Journal:  Br J Pharmacol       Date:  2004-08-31       Impact factor: 8.739

5.  Pharmacology of the urotensin-II receptor antagonist palosuran (ACT-058362; 1-[2-(4-benzyl-4-hydroxy-piperidin-1-yl)-ethyl]-3-(2-methyl-quinolin-4-yl)-urea sulfate salt): first demonstration of a pathophysiological role of the urotensin System.

Authors:  Martine Clozel; Christoph Binkert; Magdalena Birker-Robaczewska; Céline Boukhadra; Shuang-Shuang Ding; Walter Fischli; Patrick Hess; Boris Mathys; Keith Morrison; Celia Müller; Claus Müller; Oliver Nayler; Changbin Qiu; Markus Rey; Michael W Scherz; Jörg Velker; Thomas Weller; Jian-Fei Xi; Patrick Ziltener
Journal:  J Pharmacol Exp Ther       Date:  2004-05-14       Impact factor: 4.030

6.  Urotensin II acts centrally to increase epinephrine and ACTH release and cause potent inotropic and chronotropic actions.

Authors:  Anna M D Watson; Gavin W Lambert; Kathryn J Smith; Clive N May
Journal:  Hypertension       Date:  2003-07-28       Impact factor: 10.190

Review 7.  Urotensin II and cardiovascular diseases.

Authors:  George Thanassoulis; Thao Huyhn; Adel Giaid
Journal:  Peptides       Date:  2004-10       Impact factor: 3.750

Review 8.  Cardiovascular role of urotensin II: effect of chronic infusion in the rat.

Authors:  Andrew R Kompa; Walter G Thomas; Fiona See; Alex Tzanidis; Ross D Hannan; Henry Krum
Journal:  Peptides       Date:  2004-10       Impact factor: 3.750

9.  Acute cardiovascular effects of sibutramine in conscious rats.

Authors:  Jeanette Woolard; Terence Bennett; William R Dunn; David J Heal; Susan Aspley; Sheila M Gardiner
Journal:  J Pharmacol Exp Ther       Date:  2003-11-21       Impact factor: 4.030

10.  Urotensin II causes fatal circulatory collapse in anesthesized monkeys in vivo: a "vasoconstrictor" with a unique hemodynamic profile.

Authors:  Yi Zhun Zhu; Zhong Jing Wang; Yi Chun Zhu; Li Zhang; Reida M E Oakley; Chin Wee Chung; Kiat Wee Lim; How Sung Lee; Marie L Ozoux; Wolfgang Linz; Michael Böhm; Evi Kostenis
Journal:  Am J Physiol Heart Circ Physiol       Date:  2003-11-13       Impact factor: 4.733

View more
  8 in total

Review 1.  Smooth Muscle Ion Channels and Regulation of Vascular Tone in Resistance Arteries and Arterioles.

Authors:  Nathan R Tykocki; Erika M Boerman; William F Jackson
Journal:  Compr Physiol       Date:  2017-03-16       Impact factor: 9.090

Review 2.  The role of urotensin II in cardiovascular and renal physiology and diseases.

Authors:  Yi-Chun Zhu; Yi-Zhun Zhu; Philip Keith Moore
Journal:  Br J Pharmacol       Date:  2006-06-19       Impact factor: 8.739

Review 3.  Role of urotensin II and its receptor in health and disease.

Authors:  John McDonald; Madura Batuwangala; David G Lambert
Journal:  J Anesth       Date:  2007-08-01       Impact factor: 2.078

4.  Expression of urotensin II and its receptor in human liver cirrhosis and fulminant hepatic failure.

Authors:  Ludger Leifeld; Christoph Clemens; Jörg Heller; Jonel Trebicka; Tilman Sauerbruch; Ulrich Spengler
Journal:  Dig Dis Sci       Date:  2009-07-07       Impact factor: 3.199

5.  Potential Clinical Implications of the Urotensin II Receptor Antagonists.

Authors:  Philip Tsoukas; Emilie Kane; Adel Giaid
Journal:  Front Pharmacol       Date:  2011-07-22       Impact factor: 5.810

6.  Urotensin-II: More Than a Mediator for Kidney.

Authors:  Ayşe Balat; Mithat Büyükçelik
Journal:  Int J Nephrol       Date:  2012-10-10

Review 7.  Urotensin II in cardiovascular regulation.

Authors:  Fraser D Russell
Journal:  Vasc Health Risk Manag       Date:  2008

8.  A new therapeutic approach to erectile dysfunction: urotensin-II receptor high affinity agonist ligands.

Authors:  Roberta d'Emmanuele di Villa Bianca; Emma Mitidieri; Erminia Donnarumma; Ferdinando Fusco; Nicola Longo; Giuseppe De Rosa; Ettore Novellino; Paolo Grieco; Vincenzo Mirone; Giuseppe Cirino; Raffaella Sorrentino
Journal:  Asian J Androl       Date:  2015 Jan-Feb       Impact factor: 3.285

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.